( atients taking either monotherapy alone...)King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control,Health

atients taking either monotherapy alone. The trial met the secondary endpoint in that SBP reduction is statistically superior with the combination compared to either monotherapy. The SBP was reduced by 18.6 mmHg with the combination compared to 11.5 mmHg with HCT 25mg (p less than 0.001) and 10.4 mmHg with ALTACE 20mg (p=0.002).

The clinical trial was a randomized, double-blind, double-dummy, parallel-arm, multicenter study evaluating the effects of combining ALTACE 20mg and HCT 25mg once a day versus the monotherapy comparator arms of the component drugs. Patients were treated for eight weeks. A total of 341 patients comprised the intention-to-treat efficacy population. Blood pressure was measured using both a semi-automatic digital blood pressure device and 24-hour ambulatory blood pressure monitor.

A copy of the poster detailing the results of the trial and presented at ASH 2007 is available on King's website at: http://www.kingpharm.com/ashposter.asp.

About ALTACE

ALTACE is the leading branded ACE inhibitor with multiple indications. ALTACE is indicated for the treatment of hypertension. ALTACE has also been shown to reduce the risk of death in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Based upon the results of the landmark HOPE trial, ALTACE 10mg is also indicated in patients age 55 or over at high risk of developing a major CV event either because of a history of coronary artery disease, stroke or peripheral vascular disease or because of diabetes that is accompanied by at least one other CV risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of stroke, myocardial infarction, or death from CV causes. ALTACE can be used in addition to other needed treatments (such as antihypertensive, antiplatelet or lipid-lowering therapies).'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA